Verastem, Inc. (VSTM)
8.38
+0.27
(+3.33%)
USD |
NASDAQ |
Oct 09, 16:00
8.41
+0.03
(+0.36%)
After-Hours: 20:00
Verastem Enterprise Value : 706.21M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 706.21M |
| October 08, 2026 | 681.78M |
| October 07, 2026 | 695.81M |
| October 06, 2026 | 649.21M |
| October 05, 2026 | 671.83M |
| October 02, 2026 | 644.69M |
| October 01, 2026 | 662.78M |
| September 30, 2026 | 676.35M |
| September 29, 2026 | 664.59M |
| September 28, 2026 | 651.02M |
| September 25, 2026 | 648.30M |
| September 24, 2026 | 653.73M |
| September 23, 2026 | 688.12M |
| September 22, 2026 | 705.31M |
| September 21, 2026 | 670.92M |
| September 18, 2026 | 621.16M |
| September 17, 2026 | 631.11M |
| September 16, 2026 | 610.30M |
| September 15, 2026 | 612.11M |
| September 14, 2026 | 627.49M |
| September 11, 2026 | 610.30M |
| September 10, 2026 | 637.45M |
| September 09, 2026 | 666.40M |
| September 08, 2026 | 679.07M |
| September 04, 2026 | 689.93M |
| Date | Value |
|---|---|
| September 03, 2026 | 670.02M |
| September 02, 2026 | 673.64M |
| September 01, 2026 | 636.54M |
| August 31, 2026 | 601.25M |
| August 28, 2026 | 601.25M |
| August 27, 2026 | 615.73M |
| August 26, 2026 | 616.64M |
| August 25, 2026 | 588.59M |
| August 24, 2026 | 568.68M |
| August 21, 2026 | 571.40M |
| August 20, 2026 | 565.06M |
| August 19, 2026 | 608.04M |
| August 18, 2026 | 620.26M |
| August 17, 2026 | 597.63M |
| August 14, 2026 | 543.35M |
| August 13, 2026 | 551.49M |
| August 12, 2026 | 576.82M |
| August 11, 2026 | 585.87M |
| August 10, 2026 | 562.35M |
| August 07, 2026 | 557.82M |
| August 06, 2026 | 482.72M |
| August 05, 2026 | 479.10M |
| August 04, 2026 | 473.68M |
| August 03, 2026 | 462.82M |
| July 31, 2026 | 472.77M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| SELLAS Life Sciences Group, Inc. | 2.215B |
| AbbVie, Inc. | 552.84B |
| Dianthus Therapeutics, Inc. | 3.628B |
| ACADIA Pharmaceuticals, Inc. | 2.522B |
| Alnylam Pharmaceuticals, Inc. | 30.80B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -34.67M |
| Revenue (Quarterly) | 40.08M |
| Total Expenses (Quarterly) | 74.75M |
| EPS Diluted (Quarterly) | -0.3463 |
| Gross Profit Margin (Quarterly) | 89.92% |
| Profit Margin (Quarterly) | -86.51% |
| Earnings Yield | -29.36% |
| Normalized Earnings Yield | -23.93 |